Cell-Penetrating Orexin Peptide for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for narcolepsy type 1 (NT1) are limited in efficacy and rely on orexin replacement that faces challenges with permeability across the blood-brain barrier (BBB), necessitating the development of molecules that can effectively bind to both orexin receptor 1 (OR1) and OR2 after systemic administration.
Innovation Solution
A synthetic peptide, OX-DRAGON, comprising a truncated sequence of orexin A (OXA) fused with a cell-penetrating TAT peptide, designed to cross the BBB and act as an agonist for both OR1 and OR2, achieving significant anti-cataplectic effects in NT1 models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orexin replacement therapy is used for narcolepsy type 1, then therapeutic efficacy is improved, but permeability across the blood-brain barrier deteriorates
Solution Approach 1:
The patent uses a cell-penetrating peptide (CPP) as an intermediary carrier that facilitates the transport of orexin A across the blood-brain barrier. The CPP binds to the orexin A peptide, forming a complex that can traverse the BBB through cellular mechanisms, thereby delivering the therapeutic orexin A to the central nervous system while overcoming the permeability barrier.
Solution Approach 2:
The invention creates a composite peptide structure by fusing the cell-penetrating peptide sequence with the orexin A peptide sequence. This composite molecule combines the BBB-permeable properties of the CPP with the therapeutic activity of orexin A, resulting in a hybrid peptide that simultaneously achieves brain penetration and therapeutic efficacy.
2Reliability
If systemically administered orexin A is used, then therapeutic effects are achieved, but brain penetration is insufficient
Solution Approach 1:
The cell-penetrating peptide acts as a mediator that enhances the brain penetration of orexin A when administered systemically. The CPP-orexin A complex is taken up by brain cells through cellular uptake mechanisms, ensuring sufficient delivery of orexin A to the brain despite systemic administration, thereby resolving the brain penetration deficiency.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the orexin A peptide by fusing it with the cell-penetrating peptide sequence. This changes the peptide's molecular properties to include enhanced membrane permeability and cellular uptake capabilities, allowing systemically administered orexin A to effectively reach the brain.
3Ease of operation
If current narcolepsy therapies are used, then treatment is provided, but efficacy and side effects are limited
Solution Approach 1:
The cell-penetrating peptide serves as a delivery intermediary that enables effective brain penetration of orexin A, thereby improving the efficacy of narcolepsy treatment. By ensuring sufficient delivery of the active peptide to the central nervous system, the therapy achieves better therapeutic outcomes with reduced side effects compared to conventional treatments.
Solution Approach 2:
The composite peptide structure combines the advantages of orexin A (therapeutic activity) with the cell-penetrating peptide (enhanced delivery), creating a molecule that improves treatment efficacy while maintaining safety profile. This composite approach resolves the limitation of current therapies by achieving better efficacy without proportionally increasing side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
OX-DRAGON effectively promotes wakefulness, reduces cataplexy, and addresses associated symptoms of NT1 through subcutaneous administration, demonstrating potential therapeutic benefits across both central nervous system neurons and peripheral cells.
Implementation Method 1
a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants thereof
Implementation Method 2
a second peptide with orexin-receptor-1 (OR1) and orexin-receptor-2 (OR2) agonist activity
Data Source
AI summary
The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants thereof and b) a second peptide with agonist activity of OR1 and OR2 receptors or functional fragments or derivatives, or biologically active variants thereof.